Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018

PURPOSE: The optimal duration of first-line trastuzumab (T) treatment for de novo stage IV HER2-positive metastatic breast cancer (MBC) patients after complete response (CR) is not known. METHODS: A retrospective cohort study of de novo stage IV HER2-positive MBC patients who had trastuzumab include...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Henry G., Malmgren, Judith A., Guo, Boya, Atwood, Mary K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374606/
https://www.ncbi.nlm.nih.gov/pubmed/35869377
http://dx.doi.org/10.1007/s10549-022-06678-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374606/
https://www.ncbi.nlm.nih.gov/pubmed/35869377
http://dx.doi.org/10.1007/s10549-022-06678-1

Ejemplares similares